Peripheral Neuropathy Market Synopsis

Peripheral Neuropathy Market Size Was Valued at USD 2.39 Billion in 2023, and is Projected to Reach USD 5.20 Billion by 2032, Growing at a CAGR of 9.01% From 2024-2032.

The global market for peripheral neuropathy comprises the manufacture of products and therapies used to diagnose, treat and manage this disease, which affects the peripheral nerves. This market comprises of solutions including drugs, equipment like pacemakers and biologics, and innovative solutions including cell growth technologies and neural regeneration systems. Peripheral neuropathy is caused by factors like diabetes, infections, autoimmune diseases and trauma and can manifest as pain, tingling or weakness in an affected part of the body. Rising incidences of disease that lead to peripheral neuropathy globally the industry is propelled by advancing awareness, innovative solutions, and the need for effective therapies.

• The market for peripheral neuropathy is prospering owing mainly to an increasing frequency of diabetes that remains the most common cause of neuropathy all across the world. The frequency of diabetes increases year by year, and as rates of obesity and sedentary lifestyles grow, especially in developing countries, the need for tools for diagnosing and treating peripheral neuropathy also becomes urgent. Patients with peripheral neuropathy can only report pain, tingling and numbness and it has been observed to have a big impact on their lives. Moreover, this figure is increasing due to the ever-increasing population of people with neurological disorders and the aging population is vulnerable to numerous neurological disorders including peripheral neuropathy. The increasing prevalence of the condition also points to the need for the enhanced application of care approaches and techniques for the disease. Ever-improving therapeutic approaches are being discovered, as the treatment comes more in form of increased use of anticonvulsant agents and antidepressants as well as new therapeutic agents including nerve growth factor (NGF) inhibitors and neurostimulation techniques including electrical stimulation devices. They are not only improving the outcomes of treatment; they are also promoting the overall growth of the market as the providers look for better approaches to treating this condition.
• Currently, North America has the largest share in terms of the peripheral neuropathy market due to the factors like the improved healthcare infrastructure, increased healthcare spending to patient care, and a developed new therapy pipeline. Specialized care and new forms of treatment are supported by density of R & D activities in the region. However, the Asia-Pacific region is expected to show the maximum growth rate in the coming years due to several reasons: escalating awareness about peripheral neuropathy, improved healthcare facility access, and a rising geriatric population. Some of the new economy countries in this region have been experiencing enhancements in the health sector that has enhanced the diagnosis and treatment of the peripheral neuropathy. The market is headed by important competitors, who invest heavily in mergers, acquisitions, partnerships, and numerous research and developments. These strategies are intended to bolster their market standings and penetrate the putative unmet medical requirements of the peripheral neuropathy community. In the light of above mentioned facts it be concluded that peripheral neuropathy is market with vast growth prospect which can easily harness the advanced therapeutic strategy to enhance the quality of life of affected millions.

Peripheral Neuropathy Market Trend Analysis

The Impact of Diabetes and Aging on Peripheral Neuropathy

• Indeed, one of the major causes of peripheral neuropathy is diabetes given that diabetic neuropathy can develop in a large percentage of patients with diabetes. This occurs from prolonged elevated blood sugar levels that cause damage to nerves over time and lead to symptoms such as pain, tingling and loss of sensation usually in the limbs. With the subject global diabetes levels rising, WHO predicting that the count of adults with diabetes will increase up to 700 million by 2045, the incidence rate of diabetic neuropathy will also increase to match the rates. This situation is increasing the need for efficient solutions and interventions aimed at the rehabilitation of the affected nerves as well as the reduction or elimination of the observed symptoms in order to increase patients’ quality of life. With regards to this need, the healthcare providers are now turning their attention to early diagnosis and prevention of further deterioration of the condition to eliminate the immediate and long-term sequelae of diabetic neuropathy.
• Moreover, the ageing population which may be vulnerable to nerve disorders resulting from physiological changes at that stage in others, complication from other diseases. With an increase in life expectancy, it is expected that many people will develop peripheral neuropathy, raising the need for advanced treatment approaches. This demographic shift is putting pressure on pharmaceutical companies and healthcare providers to look for a wider treatment potential, whether new drugs, physical therapy, and mobility aids and therapies aimed at alleviating pain. Neuroprotection and cell regeneration research is also progressing, and aims to restore or regenerate the nerves damaged. Therefore, the market of peripheral neuropathy treatments is shifting dynamically in the particular focus of defining the integrated approach to the targeted population, mainly diabetic patients and the elderly, to treat this disabling condition more effectively.

The Future of Peripheral Neuropathy Management

• Emergent therapies for peripheral neuropathy include gene therapy and regenerative medicine hence modern unit and PP of peripheral neuropathy is changing rapidly. Such strategies are distinct from most treatments for nerve damage because they target the causes of the problem. For example, gene therapy to repair or replace the problematic genes associated with nerve degeneration, may lead to nerve regeneration and stop neuropathy. The use of regenerative medicine such as stem cell therapy tries to encourage the growth of new nerves and better general nerve health. As these advanced therapies progress further on their way, these therapies will serve as a means of a more improved life for persons suffering from peripheral neuropathy and allow the patient to gain back functionality and self-reliance.
• In parallel, the paradigm of the personalised medicine is also emerging as a new approach of combating diseases through molecular profiling of genetic and biomarkers. This approach does not only improves the quality of treatment outcomes but also reduces the side effects of the treatments since the most appropriate treatments are used on patients. Besides, there is growing improvement in the diagnostics that facilitate the early identification and control of peripheral neuropathy. Enhanced imaging services and biomarker measurements aid early intercessions needed to halt the advancement of the nerve injury. Therefore, the market related to peripheral neuropathy is increasingly transforming into a more diverse and focused on the needs of patients seen by new approaches in treatment, individualized and effectiveplans of management, improved diagnostic tools that will eventually help patient worldwide.

Peripheral Neuropathy Market Segment Analysis:

• Peripheral Neuropathy Market Segmented based on By Type, By Cause, By Treatment Type and By Distribution Channel.

By Type, Diabetic Peripheral Neuropathy (DPN) segment is expected to dominate the market during the forecast period

• Diabetic peripheral neuropathy or DPN is one of the most common complications of diabetes that is estimated to affect a huge number of patients. This complication results from a long-standing high level of blood sugar, where nerves get affected and the extremities are most affected. Main symptoms that patients with DPN complain about are sharp pains, tingling and numbness and all of these δ η is significantly affect their quality of life. Due to the progressive course of DPN it may worsen and result in formation of foot ulcers, infections, and in some cases – amputations. Since the diabetes global prevalence rises with millions of patients and the respective complications, including DPN, there is a desperate need to find adequate therapies to reduce the effects of the complication.
• The increase in diabetes incidence will be directly linked to an expected improvement in demand for therapies targeting the DPN. A variety of treatment options is being employed to address this condition, which are pharmacological, including pain, antidepressants and anticonvulsants while non-pharmacological options include physiotherapy and diet changes. Furthermore, the enhanced initial knowledge throughout health care practitioners and patients about DPN is also boosting the exploration of more effective strategies of treatment, tools and different forms of therapies for example TENS – Transcutaneous Electrical Nerve Stimulation. New pathogenic studies and investigations of more recent treatment capabilities for DPN show that the total care of this condition significantly needs reform and progress so as to raise the quality of life of diabetic patients experiencing the associated difficulties.

By Distribution Channel, Hospitals segment held the largest share in 2023

• Peripheral neuropathy treatments are mostly managed in hospitals, as they are key points where all patient related aspects can be handling with ease. They are well positioned to carry out detailed assessments, and the help of imaging techniques and nerve conduction tests in the confirmation of the degree and type of neuropathy being present. Such an assessment is important because it is the basis for the subsequent determination of the particular therapeutic intervention that can meet the specific needs of the patient. Apart from diagnosis, hospitals deliver medications, physical treatments, as well as other types of treatment methods. The presence of various specialists like, Neurologists, pain management, and physical therapist is possible, and hospitals are in a position of providing comprehensive care that enhance the delivery of services to meet the desired goals of the patent fully.
• The implementation of multi-professional working within hospitals benefits the patient as well as leads to improved care. With the integrated multidisciplinary team approach, care providers can develop more individualized therapy interventions and factors which take into account not only the patient’s therapy needs but additional medical disorders and personal habits. These allow effective management of peripheral neuropathy, but this model also incorporates continuous patient education and support – which are key in maintaining success. Additionally, as more healthcare centres integrate; affordable, quality and advanced care; they are best situated to pioneer in the formulation of effective treatment strategies and methods central to the industry causing conducive market conditions for growth of the peripheral neuropathy space. Through the enhancement of the idea of comprehensive care delivery, this model guarantees the best possible results regarding the patients’ health while participating and enhancing the development of the formation of the healthcare field.

Peripheral Neuropathy Market Regional Insights:

North American is Expected to Dominate the Market Over the Forecast period

• Thus, analytically identifying the factors contributing to such growth, the North American peripheral neuropathy market is characterized by rising demand due to increasing incidence of diabetes, which is a major contributing factor to neuropathy. As the global population continues aging, so will the rate of complications relating to diabetes, such as peripheral neuropathy, straining healthcare. The key country level demand equation is the United States, which has a well-developed health care market infrastructure that welcomes a diverse range of diagnostic and therapeutic diagnostic and treatments. Particularly, It is noteworthy that top pharmaceutical giants are focused on the development of new nerve regeneration therapies and new healing painkillers, which is crucial in meeting needs of patients with neuropathy. Such a steady flow of research and development is creating a competitive climate that helps introduce more effective treatments and better patient results.
• Furthermore, the increased knowledge of peripheral neuropathy by nurses and patients also increases market demand in North America. There are increasing awareness initiatives tagging the condition with early diagnosis/ intervention efforts thus reducing the stigma. Consequently, more focus is made on assemblage care plans, which include medical and non-medical prescribed approaches, including physiotherapy and healthy diets. All these dealing with the aim not only for helping with the symptoms of the condition but also with the life quality of the patients. Telemedicine and even remote monitoring of patients have continued to extend the innovation of peripher neuropathy, due to the ease created in management by using digital health solutions. All of these factors put together are providing a strong growth footing for the North American peripheral neuropathy market.

Active Key Players in the Peripheral Neuropathy Market

• Teikoku Pharma USA, Inc (US)
• Sun Pharmaceutical Industries Ltd (India)
• Galen Limited (US)
• Cipher Pharmaceuticals Inc (Canada)
• Mylan N.V. (US)
• Aurobindo Pharma (India)
• Zydus Cadila (India)
• Hikma Pharmaceuticals PLC (UK)
• ACI Limited (Bangladesh)
• Apotex Inc (Canada)
• Johnson & Johnson Services, Inc (US)
• Pfizer Inc (US)
• Arbor Pharmaceuticals (US)
• ALMATICA PHARMA (India)
• Alkem Labs (India)
• Amneal Pharmaceuticals LLC (US)
• Novartis AG (Switzerland)
• Lupin (India)
• Other Key Players

Key Industry Developments in the Peripheral Neuropathy Market:

• In July 2024, The U.S. Food and Drug Administration (FDA) approved a new extended-release formulation of pregabalin for the treatment of peripheral neuropathy pain. The approval represents a significant advancement in managing chronic neuropathic pain.
• In August 2024, The CMT Research Foundation (CMTRF) has allocated resources to a research initiative located at Nationwide Children’s Hospital in the United States, aimed at creating innovative methods for administering gene therapies to address various forms of Charcot-Marie-Tooth disease (CMT).
• In June, 2024 Ahmedabad-based CORONA Remedies, a pharmaceutical company has set Asia record for screening the highest number of patients for peripheral neuropathy using a biothesiometer in a single week.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Peripheral Neuropathy Market by Type
 4.1 Peripheral Neuropathy Market Snapshot and Growth Engine
 4.2 Peripheral Neuropathy Market Overview
 4.3 Diabetic Peripheral Neuropathy (DPN)
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Diabetic Peripheral Neuropathy (DPN): Geographic Segmentation Analysis
 4.4 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Chemotherapy-Induced Peripheral Neuropathy (CIPN): Geographic Segmentation Analysis
 4.5 Alcoholic Neuropathy
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Alcoholic Neuropathy: Geographic Segmentation Analysis
 4.6 Idiopathic Peripheral Neuropathy and Other Types
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Idiopathic Peripheral Neuropathy and Other Types: Geographic Segmentation Analysis

Chapter 5: Peripheral Neuropathy Market by Cause
 5.1 Peripheral Neuropathy Market Snapshot and Growth Engine
 5.2 Peripheral Neuropathy Market Overview
 5.3 Infectious Diseases
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Infectious Diseases: Geographic Segmentation Analysis
 5.4 Autoimmune Diseases
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Autoimmune Diseases: Geographic Segmentation Analysis
 5.5 Trauma or Injury
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Trauma or Injury: Geographic Segmentation Analysis
 5.6 Toxins
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Toxins: Geographic Segmentation Analysis

Chapter 6: Peripheral Neuropathy Market by Treatment Type
 6.1 Peripheral Neuropathy Market Snapshot and Growth Engine
 6.2 Peripheral Neuropathy Market Overview
 6.3 Medications
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Medications: Geographic Segmentation Analysis
 6.4 Physical Therapy
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Physical Therapy: Geographic Segmentation Analysis
 6.5 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options: Geographic Segmentation Analysis

Chapter 7: Peripheral Neuropathy Market by Distribution Channel
 7.1 Peripheral Neuropathy Market Snapshot and Growth Engine
 7.2 Peripheral Neuropathy Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Geographic Segmentation Analysis
 7.4 Pharmacies
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Pharmacies: Geographic Segmentation Analysis
 7.5 Online Platforms
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Online Platforms: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Peripheral Neuropathy Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 TEIKOKU PHARMA USA
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 INC
 8.4 SUN PHARMACEUTICAL INDUSTRIES LTD
 8.5 GALEN LIMITED
 8.6 CIPHER PHARMACEUTICALS INC
 8.7 MYLAN N.V.
 8.8 AUROBINDO PHARMA
 8.9 ZYDUS CADILA
 8.10 HIKMA PHARMACEUTICALS PLC
 8.11 ACI LIMITED
 8.12 APOTEX INC
 8.13 JOHNSON & JOHNSON SERVICES
 8.14 INC
 8.15 PFIZER INC
 8.16 ARBOR PHARMACEUTICALS
 8.17 ALMATICA PHARMA
 8.18 ALKEM LABS
 8.19 AMNEAL PHARMACEUTICALS LLC
 8.20 NOVARTIS AG
 8.21 LUPIN
 8.22 OTHER KEY PLAYERS

Chapter 9: Global Peripheral Neuropathy Market By Region
 9.1 Overview
 9.2. North America Peripheral Neuropathy Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Type
  9.2.4.1 Diabetic Peripheral Neuropathy (DPN)
  9.2.4.2 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  9.2.4.3 Alcoholic Neuropathy
  9.2.4.4 Idiopathic Peripheral Neuropathy and Other Types
  9.2.5 Historic and Forecasted Market Size By Cause
  9.2.5.1 Infectious Diseases
  9.2.5.2 Autoimmune Diseases
  9.2.5.3 Trauma or Injury
  9.2.5.4 Toxins
  9.2.6 Historic and Forecasted Market Size By Treatment Type
  9.2.6.1 Medications
  9.2.6.2 Physical Therapy
  9.2.6.3 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options
  9.2.7 Historic and Forecasted Market Size By Distribution Channel
  9.2.7.1 Hospitals
  9.2.7.2 Pharmacies
  9.2.7.3 Online Platforms
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe Peripheral Neuropathy Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Type
  9.3.4.1 Diabetic Peripheral Neuropathy (DPN)
  9.3.4.2 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  9.3.4.3 Alcoholic Neuropathy
  9.3.4.4 Idiopathic Peripheral Neuropathy and Other Types
  9.3.5 Historic and Forecasted Market Size By Cause
  9.3.5.1 Infectious Diseases
  9.3.5.2 Autoimmune Diseases
  9.3.5.3 Trauma or Injury
  9.3.5.4 Toxins
  9.3.6 Historic and Forecasted Market Size By Treatment Type
  9.3.6.1 Medications
  9.3.6.2 Physical Therapy
  9.3.6.3 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options
  9.3.7 Historic and Forecasted Market Size By Distribution Channel
  9.3.7.1 Hospitals
  9.3.7.2 Pharmacies
  9.3.7.3 Online Platforms
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Peripheral Neuropathy Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Type
  9.4.4.1 Diabetic Peripheral Neuropathy (DPN)
  9.4.4.2 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  9.4.4.3 Alcoholic Neuropathy
  9.4.4.4 Idiopathic Peripheral Neuropathy and Other Types
  9.4.5 Historic and Forecasted Market Size By Cause
  9.4.5.1 Infectious Diseases
  9.4.5.2 Autoimmune Diseases
  9.4.5.3 Trauma or Injury
  9.4.5.4 Toxins
  9.4.6 Historic and Forecasted Market Size By Treatment Type
  9.4.6.1 Medications
  9.4.6.2 Physical Therapy
  9.4.6.3 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options
  9.4.7 Historic and Forecasted Market Size By Distribution Channel
  9.4.7.1 Hospitals
  9.4.7.2 Pharmacies
  9.4.7.3 Online Platforms
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Peripheral Neuropathy Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Type
  9.5.4.1 Diabetic Peripheral Neuropathy (DPN)
  9.5.4.2 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  9.5.4.3 Alcoholic Neuropathy
  9.5.4.4 Idiopathic Peripheral Neuropathy and Other Types
  9.5.5 Historic and Forecasted Market Size By Cause
  9.5.5.1 Infectious Diseases
  9.5.5.2 Autoimmune Diseases
  9.5.5.3 Trauma or Injury
  9.5.5.4 Toxins
  9.5.6 Historic and Forecasted Market Size By Treatment Type
  9.5.6.1 Medications
  9.5.6.2 Physical Therapy
  9.5.6.3 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options
  9.5.7 Historic and Forecasted Market Size By Distribution Channel
  9.5.7.1 Hospitals
  9.5.7.2 Pharmacies
  9.5.7.3 Online Platforms
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Peripheral Neuropathy Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Type
  9.6.4.1 Diabetic Peripheral Neuropathy (DPN)
  9.6.4.2 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  9.6.4.3 Alcoholic Neuropathy
  9.6.4.4 Idiopathic Peripheral Neuropathy and Other Types
  9.6.5 Historic and Forecasted Market Size By Cause
  9.6.5.1 Infectious Diseases
  9.6.5.2 Autoimmune Diseases
  9.6.5.3 Trauma or Injury
  9.6.5.4 Toxins
  9.6.6 Historic and Forecasted Market Size By Treatment Type
  9.6.6.1 Medications
  9.6.6.2 Physical Therapy
  9.6.6.3 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options
  9.6.7 Historic and Forecasted Market Size By Distribution Channel
  9.6.7.1 Hospitals
  9.6.7.2 Pharmacies
  9.6.7.3 Online Platforms
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America Peripheral Neuropathy Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Type
  9.7.4.1 Diabetic Peripheral Neuropathy (DPN)
  9.7.4.2 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  9.7.4.3 Alcoholic Neuropathy
  9.7.4.4 Idiopathic Peripheral Neuropathy and Other Types
  9.7.5 Historic and Forecasted Market Size By Cause
  9.7.5.1 Infectious Diseases
  9.7.5.2 Autoimmune Diseases
  9.7.5.3 Trauma or Injury
  9.7.5.4 Toxins
  9.7.6 Historic and Forecasted Market Size By Treatment Type
  9.7.6.1 Medications
  9.7.6.2 Physical Therapy
  9.7.6.3 Transcutaneous Electrical Nerve Stimulation (TENS) and Surgical Options
  9.7.7 Historic and Forecasted Market Size By Distribution Channel
  9.7.7.1 Hospitals
  9.7.7.2 Pharmacies
  9.7.7.3 Online Platforms
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research